Get the Stockscreener App
11.57
0.87%
+0.10
Viatris Inc stock is currently priced at $11.57, with a 24-hour trading volume of 5.11M.
It has seen a +0.87% increased in the last 24 hours and a -0.26% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $11.49 pivot point. If it approaches the $11.63 resistance level, significant changes may occur.
Previous Close:
$11.47
Open:
$11.43
24h Volume:
5.11M
Market Cap:
$13.74B
Revenue:
$15.43B
Net Income/Loss:
$54.70M
P/E Ratio:
7.5621
EPS:
1.53
Net Cash Flow:
$2.33B
1W Performance:
+2.84%
1M Performance:
-0.26%
6M Performance:
+28.70%
1Y Performance:
+27.14%
1D Range:
$11.40
$11.65
52W Range:
$8.74
$13.62
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
724 514 1968
Address
1000 Mylan Boulevard, Canonsburg
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Icon PLC (ICLR) Beats Q1 Earnings and Revenue Estimates
Zacks Investment Research
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
Zacks Investment Research
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
Zacks Investment Research
Viatris Stock Is Still Worth Buying
Seeking Alpha
Why Is Viatris (VTRS) Down 3.5% Since Last Earnings Report?
Zacks Investment Research
Is Viatris a Great Dividend Stock or Just a Value Trap?
The Motley Fool
Viatris Inc Stock (VTRS) Financials Data
Viatris Inc (VTRS) Revenue 2024
VTRS reported a revenue (TTM) of $15.43 billion for the quarter ending December 31, 2023, a -5.14% decline year-over-year.
Viatris Inc (VTRS) Net Income 2024
VTRS net income (TTM) was $54.70 million for the quarter ending December 31, 2023, a -97.37% decrease year-over-year.
Viatris Inc (VTRS) Cash Flow 2024
VTRS recorded a free cash flow (TTM) of $2.33 billion for the quarter ending December 31, 2023, a -7.35% decrease year-over-year.
Viatris Inc (VTRS) Earnings per Share 2024
VTRS earnings per share (TTM) was $0.04 for the quarter ending December 31, 2023, a -97.66% decline year-over-year.
About Viatris Inc
Viatris Inc., a healthcare company, manufactures and distributes various medicines for patients in the United States and internationally. Its portfolio comprises approximately 1,400 approved molecules across a range of therapeutic areas, including non-communicable and infectious diseases; complex generic and branded medicines; a portfolio of biosimilars; and various over-the-counter consumer products, as well as active pharmaceutical ingredients. The company is headquartered in Canonsburg, Pennsylvania.
1.28%
0.72%
Cap:
|
Volume (24h):